Evidence-Based Management of Recurrent Pregnancy Loss (RPL)
Management of RPL focuses on targeting the specific underlying etiology identified during evaluation. When no cause is identified, supportive care remains the cornerstone of management.
Management by Identified Etiology
| Cause | Evidence-Based Intervention |
|---|---|
| Antiphospholipid Syndrome (APS) | Prophylactic dose of low-molecular-weight heparin (LMWH) and low-dose aspirin. |
| Uterine Septum | Hysteroscopic resection (septoplasty). |
| Parental Translocation | Genetic counseling and preimplantation genetic testing (PGT-SR). |
| Endocrine/Metabolic | Strict glycemic control (DM) and optimization of thyroid function (TSH < 2.5 mIU/L). |
Supportive Care for Unexplained RPL
For couples where testing reveals no clear cause, evidence strongly supports the following:
- Early Pregnancy Surveillance: Early ultrasound evaluation (starting around 6–7 weeks) for fetal cardiac activity significantly reduces anxiety and has been linked to improved outcomes.
- Lifestyle Modification: Smoking cessation, reduction of excessive alcohol and caffeine consumption, and achieving a healthy BMI.
High-Yield Exam Pearl:
- Progesterone: While controversial in the past, recent evidence (e.g., the PRISM trial) supports the use of vaginal micronized progesterone in women with early pregnancy bleeding and a history of previous RPL.
- Empiric Therapy: Avoid “shotgun” approaches. There is no role for empiric immunotherapy (e.g., IVIG, intralipid) for unexplained RPL outside of a clinical trial context.